01.002 RWE GS Aug 2022 G 19-08-2022

Yescarta real-world evidence (RWE) study enrolment two years ahead of schedule

  • Yescarta is the first CAR-T therapy approved by the FDA in the treatment of large B-cell lymphoma
  • The Center for International Blood and Marrow Transplant Research and Kite study has reached it’s enrolment target of 1,500 patients two years early
  • The FDA has required this long-term study for Yescarta which will follow the participants for at least 15 years, generating a wealth of RWE to assess long-term safety and effectiveness
Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.


DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.

For more information, please visit and contact us at